Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases  by Garibotto, Giacomo et al.
Effects of uremia and inflammation on growth
hormone resistance in patients with chronic kidney
diseases
Giacomo Garibotto1,2, Rodolfo Russo1,2, Antonella Sofia1,2, Diego Ferone2,3, Fulvio Fiorini4,
Valeria Cappelli1,2, Alice Tarroni1,2, Maria Teresa Gandolfo1, Emanuela Vigo1,2, Alessandro Valli1,
Marica Arvigo3, Daniela Verzola1, Giovanbattista Ravera5 and Francesco Minuto2,3
1Division of Nephrology, Department of Internal Medicine, Genoa, Italy; 2Genoa University and Azienda Ospedale Universita` San
Martino, Genoa, Italy; 3DISEM, Endocrinology Division and Center of Excellence for Biomedical Research, Genoa, Italy; 4Ospedale di
Sanremo, Sanremo, Italy and 5Department of Health Sciences-Biostatistics Section, Genoa, Italy
Resistance to the anabolic action of growth hormone
may contribute to the loss of strength and muscle mass in
adult patients with chronic kidney disease. We tested this
hypothesis by infusing growth hormone in patients to levels
necessary to saturate hormone receptors. This led to a
significant decrease of plasma potassium and amino acid
levels in control and hyperkalemic patients with chronic
kidney disease. These effects were completely or partially
blunted in patients with elevated C-reactive protein levels. In
forearm perfusion studies, growth hormone caused a further
decrease in the negative potassium and protein balance of
hemodialysis patients without inflammation but no effect
was seen in patients with inflammation. Only IL-6 levels
and age were found to be independent correlates in these
growth hormone-induced variations in plasma potassium
and blood amino acids. This shows that although a resistance
to pharmacologic doses of growth hormone is not a general
feature of patients with chronic kidney disease, there is a
subgroup characterized by blunted growth hormone action.
Our results support the hypothesis that uremia with
inflammation, but not uremia per se, inhibits downstream
growth hormone signaling contributing to muscle atrophy.
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Loss of muscle with protein–calorie malnutrition is relatively
common in patients with chronic renal diseases (CKD) and
is strongly associated with a negative clinical outcome.1–5
Growth hormone (GH) and insulin-like growth factor-I
(IGF-I) are potent regulators of anabolism in normal
adults.6,7 Although unproven in humans, an emergent
hypothesis is that a resistance to the anabolic drive by GH/
IGF-I may contribute to loss of energy, strength, and skeletal
and muscle mass in adult patients with CKD.6,7 Most of the
anabolic actions of GH are mediated by IGF-I, which is
produced in many different tissues.8,9 Findings in experi-
mental uremia show that the mechanisms which account for
the development of GH resistance include reduced IGF-I
synthesis8,9 sensitivity,10,11 bioavailability,12 as well as im-
paired GH signal transduction.13 In accordance with these
findings, previous elegant clinical studies have shown that the
response to IGF-1 is impaired in dialysis patients.14 However,
when IGF-I has been used in malnourished dialysis patients
an anabolic effect has been observed.15 In addition, several
clinical studies have reported that GH has a salutary effect on
body composition8,9 and muscle protein synthesis16–18 in
patients with CKD. Nonetheless, the GH response appears to
be variable.19–21 Besides uremia per se, the effectiveness of GH
might be also attenuated by other factors often found in CKD
patients, such as inflammation,22 metabolic acidosis,23,24 and
low nutrient intake.23,24 A recent 3-month trial of GH
revealed a significant increase in IGF-1 levels and markers
of bone turnover, but not lean body and fat mass, in
malnourished hemodialysis (HD) patients.19 Conversely,
Kopple et al.20 observed that GH induced a strong and
sustained anabolic effect in HD patients with protein–energy
malnutrition. The reasons for the diverging clinical effects of
GH are not understandable. Identification of variables
predicting the response to GH would offer substantial clinical
benefits.
Although chronic GH actions are IGF-I mediated, it is
now recognized that GH has direct actions via the GH
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receptor expressed in many tissues, including muscle.25 GH
can directly stimulate different biological pathways, including
lipolysis (by peroxisome proliferator-activated receptor-a
signaling),26 protein synthesis (by the stimulation of
mammalian target of rapamycin)27 and tissue potassium
uptake (by enhanced activity of Na/K ATPase pump).28
However, the effects of GH per se on potassium and amino
acid (AA) metabolism in CKD patients have never been
explored. This study was designed to provide these data and
to examine whether the acute anabolic effects of GH can be
predicted by clinical or biochemical findings.
Previous studies have shown that GH promotes nitrogen
retention and increases lean body mass and accumulation of
total body potassium.7 The present clinical investigation
explores the acute GH effects on two selected endpoints of
the anabolic GH hormone action, such as AA and potassium
metabolism, in patients with advanced CKD and controls.
We hypothesized that the GH response is blunted in uremia.
We tested this postulate via an interventional design
comprising the single administration of recombinant human
GH e.v. for 300 min. First, we monitored blood AA levels and
plasma potassium, and the GH response was analyzed in
relation to several clinical and biochemical parameters in
CKD patients. We observed that the GH response was overall
preserved, but that a blunted GH effect was present in CKD
patients with elevated C-reactive protein (CRP) plasma
levels. As a next step, we planned a study on the effects of
GH on the forearm balance of AA and potassium in
maintenance HD displaying or not an inflammatory
response.
RESULTS
Baseline and GH-induced changes in hormone and potassium
levels
GH infusion raised systemic plasma immunoradiometric
assay and immunofunctional levels of GH to a similar extent
in both patients and controls (Figure 1), with steady-state
plasma GH concentrations reached after 90 min from the
start of the infusion (coefficient of variation of GH levels
ranging from 3 to 5%). Owing to the short-term GH
administration, glucose, lactate, insulin, as well as IGF-I levels
were not significantly changed by GH (data not shown).
These findings are in accordance with previous observa-
tions.29,30
In healthy controls, the GH infusion progressively
decreased plasma potassium levels from a mean of 3.9 to
3.2 mEq/l (D plasma potassium¼0.7 mEq/l at 300 min;
Figure 2a and b), with the occurrence of mild hypokalemia
for any time beyond 150 min from the start of GH infusion.
Patients with CKD presented an increase in baseline
plasma potassium, which ranged from 4.3 to 6.6 mEq/l. The
GH infusion decreased plasma potassium from a mean of 5.5
to 4.8 mEq/l at 300 min (D plasma potassium¼0.7 mEq/l
at 300 min; Figure 2a and b) reaching levels in the upper
normal range at any time after 180 min. The overall response
of plasma potassium to GH, as well as the estimated change
in total extracellular potassium content in CKD patients were
similar to controls (area under the curve 87±17 and 90±
15 mEq/l for 300 min in patients and controls, respectively,
P¼NS; Figure 2b). When the subgroups were analyzed
in relation to CRP levels, the decline in plasma potassium
was similar to controls in CKD patients with CRP levels
lower than 5 mg/l (low CRP) or between 6 and 10 mg/l
(intermediate CRP) but it was blunted (0.4 mEq/l at
300 min) in patients with plasma CRP410 mg/l (Figure 2b;
likelihood ratio test¼ 12.15; Po0.001).
Effects of GH on blood amino-acid levels
Patients studied here presented baseline low arterial blood
levels of essential amino acids (EAA) and higher levels of
nonessential amino acids (NEAA) as compared to controls
(Po0.05). Blood levels of branched-chain amino acids
(BCAA) (335±18 vs 289±20 mmol/l) were lower (likelihood
ratio test¼ 7.9; Po0.01) in the high vs low CRP group. Only
as a trend, EAA (789±42 vs 714±63 mmol/l; P¼ 0.08) were
lower and NEAA higher (1855±120 vs 1955±88 mmol/l;
P¼NS), in the high vs low CRP group.
In healthy subjects AA levels declined by B11%
(Po0.025) after 240 min from the start of GH infusion.
This decline was statistically significant for EAA (11%;
Po0.05–0.01; Figure 3), NEAA (9%; Po0.05; data not
shown), and BCAA (11%; Po0.05; Figures 3–4).
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Figure 1 | Time-related increase in plasma growth hormone
(GH) levels during the GH infusion in patients and controls.
Systemic plasma IRMA and immunofunctional (IF) GH levels were
raised to a similar extent in both patients and controls, with
steady-state plasma GH concentrations reached after 90 min from
the start of the infusion (Po0.01 or less vs basal levels).
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The pattern of the GH-induced AA response in CKD patients
pooled together was similar to controls. Overall, blood total AA
declined by B8% (Po0.01 vs baseline, P¼NS vs controls),
NEAA by B8% (Po0.01), and EAA by B9.4% (Po0.01).
However, the decrease in blood BCAA (4%) was at the
borderline of statistical significance (Po0.07 vs basal; Figure 4).
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Figure 2 | Time-related decrease in plasma potassium concentration during GH infusion studies. Mean values at each time point are
displayed. Similarly to controls, GH progressively decreased plasma potassium in CKD patients (a). However, when the subgroups were
analyzed in relation to C-reactive protein (CRP) levels, the decline in plasma potassium was similar to controls in CKD patients with CRP
levels lower than 5 mg/l (low CRP) or between 6 and 10 mg/l (intermediate CRP), but it was blunted in patients with plasma CRP 410 mg/l
(high CRP) (Po0.001, in a mixed model analysis taking in account time, CKD and inflammation).
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Figure 3 | Effects of GH infusion on blood essential amino acids (EAA) in CKD patients and controls. In healthy subjects EAA
levels declined by B11% after 240 min from the start of GH infusion. In CKD patients, EAA declined by B9% (Po0.05 vs basal). In the
subgroup analysis, arterial concentrations of EAA were not influenced by GH in patients with plasma CRP410 mg/l (high CRP; Po0.002, by
a mixed model analysis). Statistically different from basal levels: a¼ Po0.05–0.001.
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In the subgroup analysis, in patients with high CRP,
blood levels of EAA (Figure 3) and BCAA (Figure 4)
were not influenced by GH (likelihood ratio test Po0.002
for both). By contrast, blood EAA and BCAA declined
in response to GH similar to controls, in the low
and intermediate CRP groups (likelihood ratio test,
P¼NS).
Determinants of GH-induced changes in potassium and
amino-acid levels
At univariate analysis, GH-induced variations in plasma
potassium at nadir (that is, at 210 min from the start of GH
infusion) were related to age and log interleukin-6 (IL-6), but
not to other considered variables (Table 1). By multiple
regression analysis, these two factors accounted for 41% of
variations in plasma potassium (Table 1).
At univariate analysis, variations in BCAA at nadir (that is,
at the and of the study, 300 min) over basal values (Table 1)
were related to body weight, body mass index, estimated
glomerular filtration rate, serum albumin, and inflammatory
markers, such as log-transformed CRP and IL-6. By multiple
regression analysis, however, only log IL-6 was significantly
related with GH-induced changes in BCAA levels (Table 1).
Effects of GH on net protein and potassium balance across
the forearm
This protocol was based on different timing of sampling from
the start of GH infusion (120–180 min, for the study of
380
360
340
320
300
280
260
240
220
200
0 30 60 90 120 150 180 210 240 270 300 min
Controls All CKD patients CKD patients (CRP<5 mg/l) CKD patients (CRP<10 mg/l)CKD patients (CRP 6–10 mg/l)
a
a
a
aa
a
a
a
GH
Branched-chain amino acids
Figure 4 | Effects of GH infusion on blood branched-chain amino acids (BCAA) in CKD patients and controls. In healthy subjects
BCAA levels declined by B11% after 240 min from the start of GH infusion. In CKD patients, BCAA declined by B4% (P¼NS vs basal). In
patients with plasma CRP410 mg/l (high CRP), arterial concentrations of BCAA were not influenced by GH (Po0.002, by a mixed model
analysis). Statistically different from basal levels: a¼ Po0.05.
Table 1 | Results of the regression analyses modeling changes in plasma potassium and blood BCAA induced by GH in CKD
patients (Protocol 1)
Univariate Multivariate
b s.e. t P-value b s.e. t P-value
Dependent variable: GH-induced changes in plasma potassium
Age 0.025 0.007 2.81 0.004 0.19 0.008 2.49 0.02
logIL-6 0.53 0.18 2.93 0.008 0.36 0.174 2.07 0.05
Model r2=0.41; Po0.03
Dependent variable: GH-induced changes in blood BCAA
Body weight 0.77 0.32 2.39 0.03 (a)
BMI 2.16 0.93 2.22 0.03 0.30 1.20 0.248 NS
Estimated GFR 1.859 0.97 2.39 0.03 0.85 1.23 0.687 NS
Serum albumin 24.40 10.47 2.33 0.03 14.59 10.04 1.45 NS
Log CRP 22.03 9.06 2.42 0.035 (a)
Log IL-6 17.35 5.26 3.32 0.001 12.42 5.607 2.21 0.035
Model r2=0.50; Po0.01
b, b-coefficient; BCAA, branched-chain amino acids; BMI, body mass index; CRP, C-reactive protein; GFR, glomerular filtration rate; GH, growth hormone; IL-6, interleukin-6; s.e.,
standard error.
A positive sign indicates a direct association with a low response, a negative sign indicates a negative association with a low response.
(a), not included in the multiple regression model.
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forearm potassium exchange; 240–300 min, for the study of
muscle net protein balance). During the study, in patients not
displaying an acute phase response, plasma potassium
decreased from 5.3±0.22 to 4.8±0.24 mEq/l (Po0.02;
D potassium¼0.5±0.11 mEq/l at 300 min). Similar to
what was obtained in undialyzed CKD patients, no signi-
ficant change in plasma potassium and BCAA was observed
in inflamed subjects (D potassium¼0.2±0.21 mEq/l,
D BCAA¼20±35 mmol/l; P¼NS for both). At baseline,
a forearm release of phenylalanine and potassium was obser-
ved in both groups of patients (Figures 5 and 6), indicating
the occurrence of a negative potassium and protein balance.
GH infusion caused a positive shift in the forearm potassium
balance, together with less negative net protein balance, in
noninflamed patients, while no effect was observed in
subjects with elevated CRP.
DISCUSSION
The aim of this study was to learn more about the
cause–effect relationship between GH action and uremia.
We tested the hypothesis that the acute metabolic response to
GH (an effect which is mediated by GH receptor) is impaired
in patients with advanced CKD. To examine the effects of
saturation of GH receptor, GH was raised and maintained in
a steady high pharmacologic range in patients with CKD and
in healthy controls. The effects of GH on potassium and AA
metabolism were studied in association with several different
parameters as potential predictors of the GH response.
To explore those factors that may contribute to the uremia-
related resistance to a pharmacological dose of GH, we
measured circulating concentrations of cytokines as well as
markers of acute phase response. These specific measures
were chosen in light of studies suggesting a role for these
factors in the development of resistance to GH.31 Our data
show that the GH acute anabolic response regarding two
different GH receptor-downstream pathways, namely, potas-
sium and AA metabolism, is overall preserved in patients
with advanced CKD. However, this response is blunted in
patients displaying evidence of microinflammation. Perhaps
more important than group differences, when data from all
patients were pooled, concentrations of inflammatory
markers were negatively correlated with the GH response.
Basal potassium was mildly increased in patients studied
here, in keeping with previous studies.32,33 In accordance
with changes observed in healthy volunteers, in CKD patients
GH administration was associated with a significant decline
in plasma potassium, which returned in the normal range
after 3 h. The observed potassium-lowering effect of GH is
similar to that observed for low-dose insulin (10 units plus
glucose) or nebulized albuterol (20 mg).34 However, this
response occurs later (3 h vs B30–40 min) than after insulin
or albuterol. In addition this response is very variable,
indicating that not all patients are GH-sensitive regarding the
potassium-lowering effects.
Older subjects are responsive to the metabolic effects of
GH, but this response is higher in younger individuals.35,36 In
our study, increasing age and plasma markers of inflamma-
tion were associated with decreased response to GH. In our
study, the pattern of the GH response regarding AA was
similar in patients and controls, with a small decline in
plasma total EAA and NEAA in the 240–300 min period
during the infusion. When patients were grouped separately
according to CRP levels, the GH-induced decline in
circulating BCAA and EAA was absent in the high CRP
group, suggesting that the GH-induced AA intracellular
removal is impaired in patients with an inflammatory
response. To further explore these effects, we measured
potassium and forearm muscle net protein balance in HD
patients with or without an inflammatory response. We
observed that the GH-induced stimulation of forearm
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Figure 5 | Forearm potassium balance at the baseline and
during GH infusion in hemodialysis (HD) patients with low
(o5 mg/l; &) or high (410 mg/l; ’) plasma C-reactive
protein (CRP). GH infusion caused a positive shift in forearm
potassium balance in HD patients with low CRP levels, while no
effect was observed in subjects with high CRP. Data are expressed
as mean±s.e.m. Significance of difference vs baseline value:
aPo0.03.
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Figure 6 | Forearm net protein balance at the baseline and
during GH infusion in hemodialysis (HD) patients with low
(o5 mg/l) (&) or high (410 mg/l) (’) plasma C-reactive
protein (CRP). GH infusion decreased the negative forearm
protein balance in HD patients with low CRP, while no effect was
observed in subjects with elevated CRP. Data are expressed as
mean±s.e.m. Significance of difference vs baseline value:
aPo0.03.
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potassium and AA uptake was blunted in patients with
evidence of inflammation, but it persisted in noninflamed
subjects. According to these findings, inflammation antag-
onizes the effect of GH on protein and potassium metabolism
in skeletal muscle of CKD patients.
Circulating GH-binding protein becomes saturated with
22 kDa GH (which constitutes approximately 90% of the
circulating GH) at GH concentrations above 20–30 mg/l.37 As
both uremia and inflammation have been variably associated
with low GH-binding protein expression,38 we set out to
obtain supraphysiological concentrations of GH, which were
effectively achieved (150–160 mg/l). In addition, the measure
of immunofunctional GH gave similar results in different
groups. Therefore, the effects of variable expression of
circulating GH-binding protein in different subgroups could
be ruled out.
Our results could be due to reduced expression of GH
receptor (which is unlikely, since the expression of GH
receptor seems to be unaltered by uremia)13 or reduced post-
receptor signaling. Resistance to GH may stem from impaired
GH stimulated JAK2-STAT5 phosphorylation, which may be
the result of inflammation induced SOCS2 expression.13,38–40
To our knowledge, this is the first study to demonstrate a
relationship between circulating concentrations of cytokines
and the biochemical processes that regulate the GH response
in ESRD patients. These correlations are also in keeping
with the effect of cytokines to decrease muscle protein
synthesis.41–44 Our study cannot, however, discern whether
cytokines alter the GH response in an endocrine fashion or if
the observed effects are reflective of inflammatory changes
at the level of the skeletal muscle.43–45 Regardless of the mode
of action (that is, endocrine vs paracrine/autocrine), these
findings suggest a role for inflammatory changes in the
regulation of skeletal muscle protein balance.
In this paper, we examined only some of the GH-related
pathways. Therefore, we must express caution regarding the
extension of our results to all of the GH-dependent effects in
uremia. In addition, findings reported in the present paper
are limited to the acute GH effects, and cannot predict the
true impact of GH after days or months of treatment.
In conclusion, a major finding of this study is that,
although a resistance to GH is not a generalized feature of
uremia, there is a subgroup of patients characterized by
blunted acute GH action. Aging and increase in pro-
inflammatory cytokines are independently associated with a
lessened GH response. These factors may explain, at least in
part, the heterogeneity in the response that CKD patients
show to GH therapy.
MATERIALS AND METHODS
Experimental protocols
Characteristics of the CKD (stage IV) and HD patients are given in
Table 2. Causes of CKD were chronic glomerulonephritis (n¼ 9),
hypertensive nephrosclerosis (n¼ 13), tubulointerstitial nephritis
Table 2 | Clinical characteristics of patients and control subjects
Controls
CKD subjects (Protocol 1) HD subjects (Protocol 2)
All CKD
subjects
CKD (CRP
2–5 mg/l)
CKD (CRP
6–10 mg/l)
CKD
(CRP410 mg/l)
All HD
subjects
HD (CRP
2–5 mg/l)
HD
(CRP410 mg/l)
Number of subjects 6 23 8 6 9 10 5 5
Age (years) 58±6 60±2 60±5 58±2 63±3 65±3 65±4 64±3
Gender (M/F) 5/1 19/4 7/1 5/1 7/2 8/2 4/1 4/1
BMI (kg/m2) 25±1 20±1 23±1 23±2 23±1 24±2 25±2 23±2
FFM (kg) 50±2 47±1 48±1 45±2 46±2 47±2 48±1 46±5
Fat mass (kg) 22±1 19±1 19±2 20±2 19±2 20±1 20±1 19±2
nPNA (g/kg) 1.0±0.1 0.97±0.03 0.94±0.03 0.99±0.03 0.96±0.05 1.2±0.1 1.3±0.1 1.1±0.1
SGA score 7 (6–7) 7 (4–7) 7 (4–7) 7 (6–7) 7 (4–7) 6 (5–7) 6 (6–7) 6 (5–7)
CRP (mg/l) 3 (2–4) 9 (2–25)c 4 (2–5) 8 (6–10) 12 (11–25)b,c 12 (2–40)c 4 (2–5) 20 (18–45)c
Estimated GFR
(ml/min 1.73 m2)
101±5 10±1e 10±1e 9±1e 9±1e 1±1e 1±0.4e 1±1e
HCO3 (mmol/l) 24±1 23±1 23±1 23±1 24±1 23±1 23±1 24±1
Albumin (g/100 ml) 4.0±0.1 3.9±0.03 4.0±0.1 4.0±0.1 3.7±0.1 3.8±0.2 3.8±0.1 3.7±0.3
Hemoglobin (g/100 ml) 14±1 11±0.2c 11±0.2c 11±0.3c 11±0.2c 11±0.2c 11±0.2c 11±0.2c
BUN (mg/100 ml) 12±2 77±4e 73±8e 79±5e 82±3e 78±7e 73±7e 85±6e
IGF-1 (ng/ml) 180±15 172±8 190±10 180±4 150±7 178±8 194±10 182±7
IL-6 (pg/ml) 3 (3–5) 12 (3–88)c 5 (3–7) 7 (5–12) 40 (10–88)b,c 21 (3–120)b 5 (3–5) 21 (12–120)a,d
TNF-a (pg/ml) 30 (25–32) 52 (32–160)c 42 (32–90) 60 (37–87) 56 (42–160)b,c 76 (45–212)c 68 (45–190) 84 (50–212)c
IL-1 (pg/ml) 23 (15–27) 78 (36–133)c 50 (36–66)c 77 (42–89)c 92 (50–133)c 84 (38–156) 67 (38–98)c 115 (56–156)c
Insulin (mU/ml) 7±1 8±1 6±1 9±1 8±1 12±2 12±2 13±2
GH (mg/l) 0.8±0.16 3.2±0.21c 2.3±0.44c 3.4±0.3c 3.9±0.13c 3.9±0.13c 3.7±0.1c 4.1±0.1c
BMI, body mass index; BUN, blood urea nitrogen; CKD, chronic kidney disease; CRP, C-reactive protein; FFM, fat-free mass; GFR, glomerular filtration rate; GH, growth
hormone; HD, hemodialysis; IL-1, interleukin-1; nPNA, normalized protein nitrogen appearance; SGA, subjective global assessment; TNF-a, tumor necrosis factor-a.
Data are mean±s.e.m. or median (range).
aSignificance of difference vs CKD patients with CRP o5 mg/l, Po0.05.
bSignificance of difference vs CKD patients with CRP o5 mg/l, Po0.01.
cSignificance of difference vs control subjects, Po0.05.
dSignificance of difference vs control subjects, Po0.01.
eNot tested.
942 Kidney International (2008) 74, 937–945
o r i g i n a l a r t i c l e G Garibotto et al.: Acute effects of GH on Kþ and amino acids
(n¼ 4), and polycystic renal disease (n¼ 7). Exclusion criteria were
age476 years, estimated glomerular filtration rate o7.0 ml/min,
blood bicarbonate o22 mmol/l, or the occurrence of treatable
causes of inflammation or of any illness requiring hospitalization
within the previous 30 days. Persistent increases in CRP levels
(45 mg/l on three separate weekly sampling) associated with signs
of vascular disease (coronary artery disease or peripheral artery
disease) were present in 15 CKD and 5 HD patients. There were no
differences among groups as for age, gender, body mass index,
normalized protein nitrogen appearance, fat-free and fat mass,
estimated glomerular filtration rate, blood bicarbonate, serum
albumin, hemoglobin, IGF-1, insulin, and GH levels. Calorie intake
was 30–32 kcal/kg as estimated by nutritional interviews, in CKD
patients and about 28–30 kcal/kg in HD patients. Baseline GH levels
were higher in patients as compared to controls (Po0.05). Control
subjects were on a diet providing 31–35 kcal and 1–1.1 g of protein
per kg/day, as also assessed by dietary histories and urea excretion.
Routine laboratory tests, acid-base and electrolyte measurements
were all normal. All studies were approved by the Ethical Committee
of the Department of Internal Medicine of the University of Genoa.
Patients were informed of the nature, purpose, procedure, and
possible risks before their voluntary consent was obtained.
Procedures were in accordance with the Helsinki declaration.
Patients were taking drugs, including antihypertensive drugs,
sodium bicarbonate, calcium carbonate, and erythropoietin, which
were prescribed as appropriate for each individual. Angiotensin-
converting enzyme inhibitors, angiotensin II receptor blockers, or b-
blockers, if any, were discontinued at least 10 days before the study.
Studies were performed in the postabsorptive state, and two
different protocols were used (Figure 7).
Study protocol 1: acute effects of GH on plasma potassium
and amino acids in CKD patients. A total of 23 CKD patients
were studied (Table 2). At 0700 hours, teflon catheters were placed
in an antecubital vein and a dorsal hand vein. Arterialized blood
samples46 were collected for the measuring plasma hormones,
potassium, and AA from the dorsal hand vein at the baseline and at
30-min intervals during a primed continuous infusion of GH (0.6 U;
0.7 mU/min per kg for 300 min; (Genotropin, Pharmacia, Stock-
holm, Sweden; Figure 7). The patients were divided into three
groups on the basis of inflammatory status: patients with CRP
concentrations o5 mg/l (low CRP) were classified as having no
inflammation, patients with CRP concentrations between 6 and
10 mg/l (intermediate CRP), and CRP 410 mg/l (high CRP) were
classified as having inflammation.
Study protocol 2: effects of GH on muscle net protein balance
and potassium exchange. A total of 10 maintenance HD patients
treated with bicarbonate HD for 18 months (range, 10–31 months)
were studied (Table 2). Patients were separated according to low
(2–5 mg/l) or high (410 mg/l) CRP levels. Patients were studied
after B70 h from the last dialytic treatment. Forearm muscle
potassium and net protein balance were studied in the postabsorp-
tive state.17,45,46 Catheters were inserted into a brachial artery and,
in a retrograde fashion, into the ipsilateral deep forearm vein. Blood
samples were taken simultaneously from the artery and the vein at
20-min intervals during a 60-min period. Blood flow across the
forearm was determined immediately after each arterio-venous
sampling by an indium-gallium strain gauge plethysmograph
(Angiomed Instruments, Padua, Italy). The study was performed
at the baseline and from 120 to 300 min from the start of a 300-min
primed continuous infusion of GH (0.6 U; 0.7 mU/min per kg;
Genotropin, Pharmacia) in the contralateral arm.
Assays
No tourniquet pressure was applied, and blood samples were
collected in heparin (for AA and electrolyte analyses) or EDTA-
coated (for hormones) syringes. Blood samples were accepted if the
partial pressure of oxygen was 470 mm Hg. Blood acid-base and
plasma electrolyte analysis of freshly separated plasma were
performed immediately. AA were determined in whole blood.17
Plasma potassium was measured by flame photometry (Corning 480
Flame Photometer, Corning, Medfield, MA, USA). Plasma IL-6, IL-
1, and tumor necrosis factor-a were measured in plasma samples
using enzyme-linked immunosorbent assay kits (Diaclone, Besan-
con, France), according to the manufacturer’s directions. Serum
CRP was measured by nephelometry (Behring, Deerfield, IL, USA).
AA were determined in blood by an AA analyzer (Model 3A 30,
Fisons Instr., Milan, Italy). Plasma insulin and IGF-I were
determined by radioimmunoassay (Diagnostic Products, LA, USA
and Medgenix, Fleurus, Belgium, respectively). Plasma GH was
measured by a chemiluminescent immunoradiometric assay assay
(Immulite, DPC, Los Angeles, CA, USA) and an immunofunctional
assay.47 By this technique only the GH molecules having both recep-
tor interaction sites necessary for initiation of the signal transduc-
tion process in target cells are translated into an assay signal. All
other serum chemical measurements were determined by routine
clinical chemistry laboratory procedures. Glomerular filtration
rate was estimated according to the abbreviated MDRD study
equation.48 Body composition was estimated by anthropometry.49
Calculations
The exchange of potassium and phenylalanine across the forearm
and the total decrease in extracellular potassium was calculated by
the Fick’s principle: (Xa(Xv)) plasma flow, where Xa and Xv are
the concentrations of potassium in arterial and venous plasma,
rhGH
Forearm
balance
Forearm
balance
rhGH
60 120 180 240 300 min
Arterialized
samples
Protocol 2
Protocol 1
0–30
Forearm
balance
0
min
–30 60 120 180 240 300
Figure 7 | The design of the two protocols. We studied the
acute GH effects on two selected endpoints of hormone action,
such as potassium and amino-acid metabolism, in patients with
advanced CKD and controls. We tested the hypothesis that GH
response is blunted in CKD patients via an interventional design
comprising the single administration of recombinant human
(rh)GH e.v. for 300 min. In Protocol 1, the GH-induced changes in
blood amino acids and plasma potassium were analyzed in
relation to several clinical and biochemical parameters in CKD
patients. In Protocol 2, the forearm balance of phenylalanine and
potassium was examined in the basal state and in response to GH
in hemodialysis patients displaying or not an inflammatory
response.
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respectively. Plasma flow was calculated from blood flow and
hematocrit. The forearm exchange of phenylalanine was measured
and calculated in whole blood as reported.17
Statistical analysis
All data are presented as the mean±standard error of the mean or
median (range). To establish the differences in substrate concentra-
tions between patients and controls, the unpaired t-test and one-way
analysis of variance were used. Serum CRP, IL-1, IL-6, and tumor
necrosis factor-a, were logarithmically transformed. A mixed model
accounting for repeated measures with a first order autoregressive
term and random intercept was used to analyze the time course
differences between groups. A global heterogeneity test was run
(likelihood ratio test) and post hoc comparisons were performed
when the heterogeneity test resulted statistically significant (SPlus
Professional Release 2, Math Soft Inc., Cambridge, MA, USA).
A repeated-measure analysis of variance was used to compare the
overall changes the study. When ANOVA indicated statistical
significance (Po0.05), a post hoc F-based test (Bonferroni) was
performed between phases. Relationships between variables were
sought by Pearson’s correlation coefficient and multivariate linear
regression.
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